Search

Natalie Acevedo-Seda

Behavior Analysis*

Be the first to review this provider!

Acworth, GA

Accepting new patients

Offers telehealth

Show Phone Number (470) 531-0510

Experience
Practice Locations
Reviews
Accepted Insurance
About

Clinical Overview

Natalie Acevedo-Seda works in Acworth, GA as a Behavior Analyst.
Natalie Acevedo-Seda's office accepts new patients and has telehealth appointments.

Offers Telehealth

This provider offers telehealth appointments. Call the office to schedule.

COMPARE OTHER TOP Behavioral Analysts

Contrast Natalie Acevedo-Seda with other nearby specialists.

Learn More

Learn More

Learn More

Learn More

These providers are on the medical staff of Talkspace.

Insurance & Payment Information

* Please verify this information when scheduling an appointment.

Aetna

Open Choice PPO

APCN Plus - Colorado Front Range - Choice POS II

Premier Care Network Plus - Innovation Health

Managed Choice (Open Access) POS

Whole Health Colorado Front Range

APCN Choice POS II

Choice Plus POS II

Elect Choice (Open Access) EPO

Aetna HMO

AWH Emory Northside Hospital System OAAS
CareFirst BlueCross BlueShield

HealthyBlue Advantage
Cigna

Open Access Plus

Cigna HMO

LocalPlus

Cigna PPO
Blue Cross Blue Shield

BlueCard PPO

Office Locations

Florida Autism Center
3662 Cedarcrest Rd Ste 220, Acworth, GA 30101
Directions

View All Locations

Patient Experience & Satisfaction

Be the first to leave a review

How likely are you to recommend Natalie Acevedo-Seda?

(Select your rating)

See more reviews on Healthgrades

Medical Expertise & Background

Specialties*

Behavior Analysis

*Medical News Today does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

Common Patient Questions

View all frequently asked questions View less frequently asked questions

Does Natalie Acevedo-Seda accept new patients?

Natalie Acevedo-Seda accepts new patients on Medical News Today.

Does Natalie Acevedo-Seda accept telehealth?

Natalie Acevedo-Seda accepts telehealth appointments. Please call Natalie Acevedo-Seda's office to make an appointment.

What insurance does Natalie Acevedo-Seda accept?

Natalie Acevedo-Seda accepts Aetna, CareFirst BlueCross BlueShield, Cigna and Blue Cross Blue Shield as well as many others. See all of the insurances Natalie Acevedo-Seda accepts here.

What is the address of Natalie Acevedo-Seda's office?

Natalie Acevedo-Seda's office is located at 3662 Cedarcrest Rd Ste 220 Acworth, GA 30101. Get a map and directions to Natalie Acevedo-Seda's office here.

Is Natalie Acevedo-Seda rated well by patients?

Natalie Acevedo-Seda does not have any reviews yet.

Claim Your Profile

Are you Natalie Acevedo-Seda?

Claim and manage your free profile or contact our support team.

Claim Now

Telehealth Options

This provider has not specified a telehealth appointment method. Would you still like to make an appointment with Natalie Acevedo-Seda?

Call now to make an appointment

(470) 531-0510

Know Before You Go

Preventive care: what doctors want you to know

Preventive care can help identify current or future health and medical concerns before they become major.

Find important ways to stay healthy for near years of age

Featured Stories

Moderna's mRNA flu vaccine approved by FDA. When is it available?

The FDA has approved Moderna's new mRNA flu vaccine for adults ages 50 years and older. Moderna expects the vaccine to be available in the United States for the 2026 to 2027 flu season.

Natural compound from pomegranates may help improve heart function

A natural compound derived from plant foods containing a certain type of polyphenol may help improve heart function in people with heart failure, a study in animals and human tissue models has found.

Novel mRNA vaccine plus immunotherapy reduces melanoma relapse in phase 3 trial

Moderna and Merck's neoantigen treatment, combining a personalized mRNA cancer vaccine with the immunotherapy drug pembrolizumab significantly reduced the risk of melanoma recurrence in a phase 3 trial.